Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
This bill would add two new sections to the Public Health Law focused on opioid prescribing and patient counseling. First, before issuing an initial prescription of a Schedule II controlled substance or other opioid drug for pain, and again before the third prescription in the treatment course, a practitioner would be required to discuss with the patient — or a parent/guardian for an unemancipated minor — the risks of the medication. The required discussion would cover addiction and overdose risks, the dangers of combining opioids with alcohol, benzodiazepines, or other central nervous system depressants, why the prescription is necessary, available alternatives, and the possibility of physical or psychological dependence and fatal respiratory depression.
Second, the bill would require that for the first opioid analgesic prescription in a calendar year that exceeds a one-week supply, the prescribing physician counsel the patient about overdose risks and inform the patient that an opioid antagonist, including naloxone, is available. The bill defines opioid analgesics broadly to include common opioids such as oxycodone, hydrocodone, morphine, methadone, and others, and defines opioid antagonists as FDA-approved drugs that reverse opioid effects, limited to naloxone or other drugs approved by the Department of Health for that purpose. The Department of Health would also be directed to develop and publish guidelines for the required discussions.
The bill’s impact would be to create new prescribing and counseling duties for health practitioners in New York, expanding informed-consent style requirements around opioid and pain-medication prescribing. It would affect physicians and other practitioners prescribing Schedule II controlled substances and opioid pain medications, as well as patients receiving those prescriptions, especially those starting treatment or receiving a first longer-than-one-week opioid prescription in a calendar year. It would also give the Department of Health a role in standardizing the counseling through guidance and would reinforce awareness of naloxone availability.
The overall sentiment reflected by the bill text is preventive and public-health oriented, with the measure aiming to reduce opioid misuse, overdose, and dependence through mandatory patient education. No committee transcript or vote record was provided, so there is no documented debate or recorded support/opposition in the materials supplied. Based on the bill’s structure, it appears designed as a patient-safety measure rather than a punitive restriction on prescribing.
Potential points of contention would likely center on whether the counseling mandates add administrative burden or interfere with clinical discretion, versus whether they are necessary to improve informed prescribing and overdose prevention. Another possible issue is the breadth of the required discussions and whether practitioners will need additional training or standardized materials to comply consistently. The bill also may raise questions about how strictly the one-week threshold and annual first-prescription rule would be applied in practice.
The bill would amend the Public Health Law by creating new sections 3309-c and 3309-d, imposing affirmative counseling obligations on practitioners before certain opioid and pain-medication prescriptions are issued. It would require disclosure of addiction, overdose, dependence, and drug-interaction risks, and would require counseling on naloxone or another approved opioid antagonist for the first opioid analgesic prescription of the year exceeding one week. The Department of Health would be tasked with issuing practitioner guidelines, and the act would take effect 120 days after becoming law, with immediate authorization for implementing regulations.
The bill’s apparent sentiment is strongly public-health and harm-reduction oriented. It seeks to increase patient awareness of opioid risks and encourage overdose prevention through counseling and naloxone education. Because no committee discussion or vote history is available, there is no direct evidence of legislative support or opposition in the record provided, but the bill itself reflects a cautious, safety-focused approach to opioid prescribing.
No formal contention is documented in the provided materials, but the likely areas of debate are the added compliance burden on prescribers, the scope and timing of the required counseling, and whether the state should mandate specific conversations for opioid prescribing. Supporters would likely emphasize overdose prevention, informed consent, and naloxone awareness, while critics may argue that the requirements could be duplicative of existing clinical practice or create administrative hurdles for pain management.